Determinants of restenosis and lack of effect of dietary supplementation with eicosapentaenoic acid on the incidence of coronary artery restenosis after angioplasty.
The effect of an eicosapentaenoic acid-rich encapsulated preparation of fish oil on the incidence of early restenosis after coronary angioplasty was assessed by a randomized double-blind placebo-controlled study. A total of 108 patients received either 10 capsules of fish oil (1.8 g eicosapentaenoic acid, 1.2 g docosahexaenoic acid) or 10 control capsules (50% olive oil, 50% corn oil), commencing the day before angioplasty and continuing for 4 months after angioplasty, in addition to treatment with aspirin and verapamil. In 101 (94%) of the 108 patients, follow-up angiographic or postmortem result was evaluated at a mean (+/- SD) of 100 (+/- 22) days. Angiographic restenosis was observed in 34% of patients (29% of lesions) in the fish oil-treated group and 33% of patients (31% of lesions) in the control group (no significant difference). The overall incidence of angiographic restenosis was significantly higher in patients with 1) recurrent angina pectoris, 2) a positive exercise test at follow-up after angioplasty, 3) residual stenosis greater than 30% immediately after angioplasty, and 4) dilation of the left anterior descending or right coronary artery. Biochemical investigations showed a greater decrease in the serum triglyceride levels in the fish oil-treated group versus the control group (p less than 0.05) but no differences between the two groups in cholesterol levels or platelet counts over the 4 month period. In conclusion, in this study, the administration of fish oil at a dose of 10 capsules/day did not reduce the incidence of early restenosis after coronary angioplasty.
Grigg
L E
LE
Department of Cardiology, Royal Melbourne Hospital, Victoria, Australia.
Kay
T W
TW
Valentine
P A
PA
Larkins
R
R
Flower
D J
DJ
Manolas
E G
EG
O'Dea
K
K
Sinclair
A J
AJ
Hopper
J L
JL
Hunt
D
D
D000328:Adult; D000800:Angioplasty, Balloon; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000097:blood; D002784:Cholesterol / Q000097:blood; D003327:Coronary Disease / Q000000981:diagnostic imaging / Q000517:prevention & control* / Q000628:therapy; D004311:Double-Blind Method; D015118:Eicosapentaenoic Acid / Q000097:blood / Q000627:therapeutic use*; D005260:Female; D005395:Fish Oils / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011859:Radiography; D011897:Random Allocation; D012008:Recurrence; D012307:Risk Factors
D001095:Arachidonic Acids; D005395:Fish Oils; D016718:Arachidonic Acid; D002784:Cholesterol; D015118:Eicosapentaenoic Acid